Skip to main content
Premium Trial:

Request an Annual Quote

Codon Devices to Develop Enzymes for Agrividia’s Corn-based Ethanol Program

NEW YORK (GenomeWeb News) - Codon Devices will use its BioLogic engineering platform to develop enzymes to be used in ethanol production by the agro-biotechnology company Agrividia.
Codon said the agreement with Agrividia, which will include royalties and performance-based payments, is part of its newly launched BioLogic Engineering Partnering Program.
The BioLogic platform is used in the “design, discovery and optimization of proteins for specific applications,” and relies on the company’s BioFab Production Platform, which makes low-cost synthetic genes, Codon said.
Agrividia plans to use enzymes Codon develops to break down the entire corn plant, including the leaves, stalks, and husks, which account for around fifty percent of the total biomass yield per acre, Codon said. These parts of the corn plant currently cannot be converted into ethanol in an economical manner. Enzymes based on those that already exist in the plant that could break down parts of the whole organism for use as ethanol could greatly increase yield, and make corn-based ethanol a more viable option for mass biofuel, the company said.
"With traditional approaches to developing such enzymes, this normally would be a one- to two-year project with no certainty of the outcome,” said Codon’s CSO, Brian Baynes, in a statement. With the new engineering platform, he said the company expects to be able to deliver these optimized enzymes to Agrividia in six to nine months.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.